Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Melanoma 5Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lung Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Waldenstrom Macroglobulinemia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms 2Wilms Tumor 1Uveal Melanoma 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

Etoposide 10Cisplatin 7Carboplatin 6tislelizumab 2camrelizumab 2atezolizumab 2anlotinib 2Topotecan 2Irinotecan 2Drug Therapy 2Bevacizumab 2temsirolimus 1spartalizumab 1oblimersen 1obinutuzumab 1lutetium Lu 177 dotatate 1gossypol acetic acid 1durvalumab 1ceralasertib 1apatinib 1Temozolomide 1Sirolimus 1Podophyllotoxin 1Platinum 1Paclitaxel 1NVP-BKM120 1Injections 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Small Cell Lung Cancer × oblimersen × Clear all
NCT00017251 2013-01-24

Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡